Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Hyperinsulinemic diseases of civilization: more than just Syndrome X.

Cordain L, Eades MR, Eades MD.

Comp Biochem Physiol A Mol Integr Physiol. 2003 Sep;136(1):95-112. Review.

PMID:
14527633
2.

Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.

Reaven GM.

Panminerva Med. 2005 Dec;47(4):201-10. Review.

PMID:
16489319
3.

Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.

Pawelczyk L, Spaczynski RZ, Banaszewska B, Duleba AJ.

Eur J Obstet Gynecol Reprod Biol. 2004 Apr 15;113(2):209-13.

PMID:
15063962
4.

Polycystic ovary syndrome and type 2 diabetes mellitus.

De Leo V, Musacchio MC, Morgante G, La Marca A, Petraglia F.

Minerva Ginecol. 2004 Feb;56(1):53-62. Review.

PMID:
14973410
5.

Childhood obesity and insulin resistance.

Maclaren NK, Gujral S, Ten S, Motagheti R.

Cell Biochem Biophys. 2007;48(2-3):73-8.

PMID:
17709876
6.

Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.

Resmini E, Minuto F, Colao A, Ferone D.

Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Review.

PMID:
19322513
8.

Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.

Berker B, Emral R, Demirel C, Corapcioglu D, Unlu C, Kose K.

Gynecol Endocrinol. 2004 Sep;19(3):125-33.

PMID:
15697073
10.

Endometrium in PCOS: Implantation and predisposition to endocrine CA.

Giudice LC.

Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):235-44. Review.

PMID:
16772154
11.

Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome.

Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM.

Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):371-6.

PMID:
16915540
12.

Energy balance, physical activity, and cancer risk.

Fair AM, Montgomery K.

Methods Mol Biol. 2009;472:57-88. doi: 10.1007/978-1-60327-492-0_3. Review.

PMID:
19107429
13.

Hemorheological aspects of the metabolic syndrome: markers of insulin resistance, obesity or hyperinsulinemia?

Brun JF, Aloulou I, Varlet-Marie E.

Clin Hemorheol Microcirc. 2004;30(3-4):203-9.

PMID:
15258344
14.

Hyperandrogenism, insulin resistance and hyperinsulinemia as cardiovascular risk factors in diabetes mellitus.

García-Romero G, Escobar-Morreale HF.

Curr Diabetes Rev. 2006 Feb;2(1):39-49. Review.

PMID:
18220616
16.

The metabolic syndrome in young Korean women with polycystic ovary syndrome.

Park HR, Choi Y, Lee HJ, Oh JY, Hong YS, Sung YA.

Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S243-6. Epub 2007 Jul 3.

PMID:
17610984
17.

Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome.

Thomann R, Rossinelli N, Keller U, Tirri BF, De Geyter C, Ruiz J, Kränzlin M, Puder JJ.

Gynecol Endocrinol. 2008 Apr;24(4):199-206. doi: 10.1080/09513590801893398.

PMID:
18382906
19.

Managing atherosclerosis in patients with type 2 diabetes mellitus and metabolic syndrome.

Venkatapuram S, Shannon RP.

Am J Ther. 2006 Jan-Feb;13(1):64-71. Review.

PMID:
16428924
20.

Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome?

Starka L, Duskova M, Cermakova I, Vrbiková J, Hill M.

Endocr Regul. 2005 Dec;39(4):127-31.

PMID:
16552990

Supplemental Content

Support Center